Ebola Claims Land Firms In SEC Doghouse, NAD Review
This article was originally published in The Tan Sheet
Executive Summary
SEC suspends trading for four firms linked to fraudulent Ebola claims and issues an investor alert about the potential for fraud in microcap companies purportedly involved in preventing, testing or treating the virus. Meanwhile, NAD reports an online retailer discontinued an ebola claim for its herbal supplement.
You may also be interested in...
Ebola Crisis Causes Drug Claim Symptoms In Products Marketed As Supplements
FTC joins FDA in one of the three warning letters to firms claiming their products can either prevent or treat Ebola. One firm’s website offers a video titled, “Urgent Message to Ebola-Stricken Nations' Heads of State,” and another claims “primary uses for oregano include athlete’s foot, candida, canker sores, Ebola virus.”
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.